Please login to the form below

Not currently logged in
Email:
Password:

orphan drug

This page shows the latest orphan drug news and features for those working in and with pharma, biotech and healthcare.

Shionogi and F2G partner to develop antifungal treatment olorofim

Shionogi and F2G partner to develop antifungal treatment olorofim

It also covers azole-resistant strains, coccidioidomycosis and scedosporiosis (including lomentosporiosis). The treatment has already been granted orphan drug status by the European Medicines Agency (EMA) and orphan drug status, Qualified

Latest news

More from news
Approximately 6 fully matching, plus 259 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 57 partially matching documents found.

Latest appointments

  • New faces at Lucid Group and ZPB Associates New faces at Lucid Group and ZPB Associates

    Most recently, she worked in the consultancy’s rare diseases division, where is provided crisis management support in pricing/access barriers for an orphan drug.

  • Recruiters PIR International appoint four new executives Recruiters PIR International appoint four new executives

    Whilst working with multi-nationals he has assisted US headquartered specialty and orphan drug companies establish their European infrastructure.

  • New hires at Nanoform, Leo Pharma and Calliditas New hires at Nanoform, Leo Pharma and Calliditas

    The combination of his strong experience in regulatory affairs, not only with the FDA but on a broad international basis with a proven track record and experience from orphan drug development ... During his time at Novo Nordisk, he led the strategic

  • Novo Nordisk target Ablynx reshuffles its board Novo Nordisk target Ablynx reshuffles its board

    Dr Hensen’s expertise lies in orphan drug research and development, international marketing and commercialisation and has experience in regulatory, pharmacovigilance, medical marketing and business development knowledge.

  • Dr Irina Antonijevic joins vasopharm Dr Irina Antonijevic joins vasopharm

    In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... She brings over 15 years of global drug development experience in neuroscience to vasopharm

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Improving healthcare for rare disease patients Improving healthcare for rare disease patients

    The main way that pharma companies can overcome this barrier is through orphan drug designation, where incentives are given to encourage research into rare disease treatments that fit a specific criteria. ... Published July 21, 2021. Accessed March 1,

  • Rare Disease Day – looking to the future with hope Rare Disease Day – looking to the future with hope

    The interest from the pharmaceutical industry is also significant. Orphan drug sales are expected to account for approximately 20% of US drug sales by 2024, and the non-profit organisation Global ... themes to advance their goal) recently published in

  • Welcome to the era of the orphan drug Welcome to the era of the orphan drug

    However, the passing of the Orphan Drug Act by the FDA in 1983 and the reciprocal Orphan Drug Regulation by the European Union in 1999 has helped to incentivise drug development ... Fast-forward around 30 years and we have entered a new era – an era of

  • Rare Disease Day – why it’s important to show your stripes Rare Disease Day – why it’s important to show your stripes

    A standardised definition for rare diseases is currently lacking, with incidences typically defined by regional legislations developed to incentivise drug development (termed ‘orphan medicines/drugs’ by the FDA and EMA). ... disease drug development

  • Reflections of a Fireside Chat from the World Orphan Drug Congress 2020 Reflections of a Fireside Chat from the World Orphan Drug Congress 2020

    Hear from Trish Shepherd COO, Patient &Brand Communications, OPEN Health. From junior doctor to gene therapy CEO, how one person’s drive to make rare disease curable is shaping the future of medicine. It was a truly touching story to hear Dr

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...